Consensus costing and volume forecasting guide bacteriology laboratory implementation in sub-Saharan Africa
The study reports a consensus-driven costing and forecasting model to establish functional clinical bacteriology laboratories in secondary and tertiary hospitals across sub-Saharan Africa. Investigators estimated mean consumable costs at $6.23 per hospital admission and $10.86 per septic episode investigation under minimal and standard scenarios, respectively, with initial equipment establishment costing approximately $30,763. The framework incorporates expected positivity rates and reagent usage derived from accredited laboratories in Benin and Ethiopia to enable tailored procurement planning. These findings provide health administrators and funders with transparent benchmarks for supply chain management and testing volume forecasting, directly supporting antimicrobial resistance action plans in resource-limited settings.
The original study
Minimal supply chain and forecasting testing volumes for clinical bacteriology laboratories in resource-limited settings for individual patient care: a costing study.
- Authors
- Semret M, Ajibola O, Barbé B, Campbell JR, Ondoa P, Affolabi D, et al.
- Journal
- The Lancet. Microbe
- Type
- Journal Article
- PMID
- 42542126
Original abstract
BACKGROUND: Inadequate access to clinical bacteriology testing in low-resource settings compromises individual patient care and contributes to antimicrobial resistance. Funders, policy makers, and health administrators working to expand bacteriology testing in sub-Saharan Africa require evidence-based guidance. The aim of this study was to assemble a costed consensus list of minimum equipment and consumables required to implement and operate a functional clinical bacteriology laboratory in secondary and tertiary care hospitals in sub-Saharan Africa, to guide funders and health administrators. METHODS: A consensus list of minimum materials for diagnosing bloodstream infections was assembled by experts from Africa, North America, and Europe, representing academia, funders, and implementers. A modelling study was performed to estimate costs across several testing scenarios developed using a formal framework for forecasting testing volumes and reagent usage. Outcomes assessed were consumable costs per hospital admission and per investigation of septic episode and costs of non-recurring items at the time of establishment of a laboratory. Data from two accredited bacteriology laboratories providing individual patient care in Benin and Ethiopia were used to inform expected positivity rates, reagent usage, and testing volumes. Supplier quotes from North America and Europe were used to provide average unit costs and 95% uncertainty ranges. FINDINGS: The estimated mean consumable cost per hospital admission was, in 2023 USD, $6·23 (95% uncertainty range 5·42-7·54) in the strict minimum scenario and $10·86 (9·82-12·31) in the standard scenario. The mean cost for the minimal equipment list at the time of establishment of a laboratory was estimated at $30 763 (28 403-33 043; plus an annual equipment maintenance cost of $3076 [2840-3304]), which includes purchase of commercial quality control strains and other non-recurring consumables. Available data suggest that costs from national distributors in sub-Saharan Africa could be three-fold higher than those described. Finally, we provide a transparent and adaptable basis for estimating minimal testing volumes and reagent usage, enabling tailored procurement planning in regions currently without clinical bacteriology laboratories. INTERPRETATION: These results inform national antimicrobial resistance action plans on supply procurement, costing, and the ability to benchmark and forecast minimal acceptable testing volumes for the diagnosis of bloodstream infections for individual patient care. FUNDING: Fonds de recherche du Québec - Santé.